pseudoxanthoma elasticum
Recently Published Documents


TOTAL DOCUMENTS

1230
(FIVE YEARS 214)

H-INDEX

54
(FIVE YEARS 6)

Author(s):  
Akira Iwanaga ◽  
Atsushi Utani ◽  
Yuta Koike ◽  
Yumi Okubo ◽  
Yutaka Kuwatsuka ◽  
...  

Biomedicines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1895
Author(s):  
Max Jonathan Stumpf ◽  
Nadjib Schahab ◽  
Georg Nickenig ◽  
Dirk Skowasch ◽  
Christian Alexander Schaefer

Pseudoxanthoma elasticum (PXE) is a rare, genetic, metabolic disease with an estimated prevalence of between 1 per 25,000 and 56,000. Its main hallmarks are characteristic skin lesions, development of choroidal neovascularization, and early-onset arterial calcification accompanied by a severe reduction in quality-of-life. Underlying the pathology are recessively transmitted pathogenic variants of the ABCC6 gene, which results in a deficiency of ABCC6 protein. This results in reduced levels of peripheral pyrophosphate, a strong inhibitor of peripheral calcification, but also dysregulation of blood lipids. Although various treatment options have emerged during the last 20 years, many are either already outdated or not yet ready to be applied generally. Clinical physicians often are left stranded while patients suffer from the consequences of outdated therapies, or feel unrecognized by their attending doctors who may feel uncertain about using new therapeutic approaches or not even know about them. In this review, we summarize the broad spectrum of treatment options for PXE, focusing on currently available clinical options, the latest research and development, and future perspectives.


2021 ◽  
Author(s):  
Luca Fésűs ◽  
Dóra Plázár ◽  
Attila Kolonics ◽  
Ludovic Martin ◽  
Norbert Wikonkál ◽  
...  

2021 ◽  
Author(s):  
Paige Boneski ◽  
Vedavathi Madhu ◽  
Ryan Tomlinson ◽  
Koen Van de Wetering ◽  
Irving Shapiro ◽  
...  

Chronic low back pain is a highly prevalent health condition intricately linked to intervertebral disc degeneration. One of the prominent features of disc degeneration that is commonly observed with aging is dystrophic calcification. ATP-binding cassette sub-family C member 6 (ABCC6), a presumed ATP efflux transporter, is a key regulator of systemic levels of the mineralization inhibitor pyrophosphate (PPi). Mutations in ABCC6 result in pseudoxanthoma elasticum (PXE), a progressive human metabolic disorder characterized by mineralization of the skin and elastic tissues. The implications of ABCC6 loss-of-function on pathological mineralization of structures in the spine, however, are unknown. Using the ABCC6 -/- mouse model of PXE, we investigated age-dependent changes in the vertebral bone and intervertebral disc. ABCC6 -/- mice exhibited diminished trabecular bone quality parameters at 7-months which remained significantly lower than the wild-type mice at 18 months-of-age. ABCC6 -/- vertebrae showed increased TRAP staining along with decreased TNAP staining, suggesting an enhanced bone resorption as well as decreased bone formation. Surprisingly, however, loss of ABCC6 resulted only in a mild, aging disc phenotype without evidence of dystrophic mineralization. Finally, we tested the utility of oral K3Citrate to treat the vertebral phenotype since it is shown to regulate hydroxyapatite mechanical behavior. The treatment resulted in inhibition of osteoclastic response and an early improvement in mechanical properties of the bone underscoring the promise of potassium citrate as a therapeutic agent. Our data suggest that although ectopic mineralization is tightly regulated in the disc, loss of ABCC6 compromises vertebral bone quality and dysregulates osteoblast-osteoclast coupling.


Author(s):  
Gabrielle Brokamp ◽  
Mari Mori ◽  
Esteban Fernandez Faith

2021 ◽  
Author(s):  
Eszter Kozák ◽  
Krisztina Fülöp ◽  
Natália Tőkési ◽  
Nidhi Rao ◽  
Qiaoli Li ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document